The canonical profile remains the primary reading view. Read the canonical profile.
We added a plain-language reader guide with cited answers, re-checked FDA’s MOTS-c briefing, and added HHS’s October 30, 2026 draft enforcement-discretion policy, which lists MOTS-c acetate. FDA has not issued a final 503A rule. 256
What this version reported
FDA staff recommended in May 2026 against adding MOTS-c to the 503A compounding list, and FDA has not issued a final rule. An October 30, 2026 HHS draft enforcement-discretion policy lists MOTS-c acetate among six peptides for which HHS says it does not intend to take enforcement action against licensed compounders who meet its conditions; it does not make MOTS-c an FDA-approved drug.↗↗↗↗
Reader guide in this version
Key takeaway
MOTS-c is a 16-amino-acid peptide encoded in mitochondrial DNA, first described by researchers in 2015, and the research on it comes from rodent and laboratory studies.2 It is not an FDA-approved drug, and FDA’s 2026 evaluation found no product containing it authorized in the European Union.2 FDA found no clinical studies or other human exposure data for MOTS-c, so its effects and safety in people are unknown.2 FDA staff recommended against adding MOTS-c to the list of substances pharmacies may use in compounding, but an October 2026 HHS draft policy lists it among six peptides for which HHS says it does not intend to take enforcement action against licensed compounders who meet its conditions while FDA’s rulemaking continues.2,5,6
At a glance
- What it is
- A naturally occurring 16-amino-acid peptide encoded in mitochondrial DNA. FDA’s evaluation covers synthetic free-base and acetate forms.2
- FDA status
- Not FDA-approved. FDA staff recommended in May 2026 against adding MOTS-c to the 503A compounding list, and FDA has not issued a final rule. Under an October 30, 2026 HHS draft enforcement-discretion policy, MOTS-c acetate is one of six listed peptides; HHS says it does not intend to take enforcement action against licensed pharmacies, federal facilities or physicians that compound it under the policy’s conditions.2,5,6
- Human evidence
- None found by FDA for MOTS-c itself. HHS’s policy document cites a placebo-controlled trial of a related analogue.2,6
- Sport status
- FDA’s briefing notes that MOTS-c appears as a prohibited substance in the Global Drug Reference Online database, which draws on the World Anti-Doping Agency’s 2024 prohibited list, as FDA checked in March 2024.2
- Evidence strength
- Animal and lab studies only
What is MOTS-c?
MOTS-c stands for mitochondrial open reading frame of the 12S rRNA-c. It is a peptide of 16 amino acids that cells make from a short stretch of mitochondrial DNA, and it circulates naturally in the blood of humans and rodents.2
Researchers first described MOTS-c in 2015. FDA could not determine how long it has been used in pharmacy compounding, and outsourcing facilities reported no products containing it from 2017 to December 2025.2
FDA found MOTS-c marketed online, alone and in combination with other substances, for uses including metabolism, weight loss, physical performance and slowing cellular aging.2
How is MOTS-c thought to work?
In rodent studies, MOTS-c affected glucose and fat metabolism, bone remodeling and blood vessels, apparently through a cellular energy-sensing pathway known as AMPK.2
FDA cautions that these findings come only from rodent models, that the studies did not test whether larger amounts produced larger effects, and that MOTS-c’s molecular targets remain unknown, which makes it hard to predict which organs it would affect.2
A laboratory study found that MOTS-c is broken down quickly in human blood, which FDA says raises the question of whether giving it from outside the body can reach active levels.2
What do human studies show?
FDA’s review found none. FDA did not identify any clinical study evaluating MOTS-c in people, and the twelve references submitted to FDA in support of MOTS-c included no clinical studies.2
FDA found no pharmacokinetic data in people, and its searches of FDA’s adverse-event database through March 2025 found no reports.2
HHS’s policy document cites a randomized, placebo-controlled trial of a MOTS-c analogue that it says reported no serious adverse events. That trial tested a related compound, not MOTS-c itself, and the policy document does not identify it further.6
FDA concluded that there is a lack of evidence to evaluate whether MOTS-c works for the proposed uses and that its safety risks in people are unknown.2
What the evidence base contains
- Animal or laboratory research Mouse and rat studies reporting less diet-induced weight gain, better insulin sensitivity, effects on bone, and less blood-vessel calcification. FDA notes that the studies did not test whether larger amounts produced larger effects.2
- Animal or laboratory research A laboratory study reporting that MOTS-c is broken down quickly in human blood.2
Evidence-strength label: Animal and lab studies only. How this label is assigned
Is MOTS-c FDA-approved?
No. FDA’s May 2026 evaluation states that neither MOTS-c free base nor MOTS-c acetate is a component of an FDA-approved drug and that there is no United States Pharmacopeia monograph for either.2
Under section 503A of the federal drug law, the list of bulk substances that pharmacies can use in compounding, known as the 503A bulks list, is being developed through FDA rulemaking.5
FDA staff evaluated both forms of MOTS-c for that list and recommended against adding either. They cited poor chemical characterization, unknown extent of use, no nonclinical toxicity data, and no clinical studies of safety or effectiveness. FDA’s meeting page lists obesity and osteoporosis as the uses FDA reviewed, and FDA notes that approved treatments exist for both.2,3
HHS’s policy document states that MOTS-c was in FDA’s Category 2, the group of nominated substances that may present significant safety risks, from September 29, 2023 until April 22, 2026, and that neither change altered its status under section 503A.1,6
FDA’s Pharmacy Compounding Advisory Committee discussed MOTS-c on July 23, 2026. HHS’s policy document states that the committee voted in favor of both forms, while FDA’s drug-review center had recommended against listing either form. FDA’s own meeting page, last updated August 6, 2026, lists no vote record.2,3,6
On October 30, 2026, HHS published notice of a draft policy saying it does not intend to take enforcement action against licensed pharmacies, federal facilities or physicians compounding with the peptide substances listed in the policy’s appendix while the 503A list is developed. HHS calls it an interim policy, says it is not binding, and says it may be revisited if safety or quality problems arise.5,6
Appendix A of the policy lists six peptides: BPC-157, Epitalon, KPV, MOTS-c, Semax and TB-500. For MOTS-c, the policy covers only the acetate salt form. It applies only when its conditions are met, including a patient-specific prescription, a single listed active ingredient, bulk substance from an FDA-registered facility with a certificate of analysis, and reporting of serious adverse events to FDA.6
HHS and FDA staff weigh the same record differently. HHS’s policy document says newer certificates from FDA-registered manufacturers supply the quality test results FDA staff found missing, that use is now documented, and that the available safety evidence, including the analogue trial and rodent studies, points in one direction. FDA staff had found no human data on MOTS-c at all.2,6
The policy does not make MOTS-c an FDA-approved drug and is not an FDA rule. HHS notes that FDA does not review compounded drugs for safety, effectiveness or quality before they are marketed.5,6
Timeline
- Researchers first describe MOTS-c, according to the literature FDA reviewed.2
- MOTS-c is placed in FDA’s Category 2 of nominated compounding substances that may present significant safety risks, according to HHS’s policy document.6
- A Federal Register notice announces the July advisory-committee meeting that will discuss MOTS-c and opens a public comment docket.4
- MOTS-c leaves Category 2, according to HHS’s policy document.6
- FDA staff date their evaluation recommending that MOTS-c not be added to the 503A bulks list.2
- FDA’s Pharmacy Compounding Advisory Committee discusses MOTS-c.3
- HHS publishes notice of a draft enforcement-discretion policy whose Appendix A lists MOTS-c among six peptide substances used in compounding.5,6
What is still unknown?
Whether MOTS-c has any benefit in people: FDA found no clinical studies of it for any condition.2
Its safety in people, whether it can trigger immune reactions, and whether it stays in the blood long enough to act.2
What is in products sold under the name: FDA notes that the free-base and acetate forms are distinct substances and that inconsistent naming is a safety risk.2
Whether FDA’s rulemaking will add MOTS-c to the 503A list, and how long the October 2026 HHS interim policy will remain in place, remained unresolved in the sources reviewed through November 14, 2026.2,5,6
Sources for this version
- 1Certain bulk drug substances for use in compounding that may present significant safety risks ↗
U.S. Food and Drug Administration · Official source · Source checked November 14, 2026
- 2FDA briefing document for MOTS-c ↗
U.S. Food and Drug Administration · Official source · Source checked November 14, 2026
- 3July 23-24, 2026 Pharmacy Compounding Advisory Committee meeting ↗
U.S. Food and Drug Administration · Official source · Source checked November 14, 2026
- 4Federal Register notice 2026-07361 · published 2026-04-16 · Pharmacy Compounding Advisory Committee; Notice of Meeting; Establishment of a Public Docket; Request for Comments-Bulk Drug Substances Nominated for Inclusion on the Section 503A Bulk Drug Substances List ↗
Federal Register via GovInfo · Official source · Source checked August 21, 2026
- 5Enforcement Discretion Policy Regarding 503A Compounding Using Certain Peptide Bulk Drug Substances · notice of availability · 91 FR 68526 · October 30, 2026 ↗
Federal Register · U.S. Department of Health and Human Services · Official source · Source checked November 14, 2026
- 6HHS Enforcement Discretion Policy Regarding 503A Compounding Using Certain Peptide Bulk Drug Substances, with Appendix A (list of peptides) and Appendix B (identities and justifications) ↗
U.S. Department of Health and Human Services · Official source · Source checked November 14, 2026